vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and HEALTHSTREAM INC (HSTM). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $79.7M, roughly 1.7× HEALTHSTREAM INC). On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 7.4%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $13.0M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 4.7%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
HealthStream Inc is a leading U.S.-based provider of workforce development, compliance, and training solutions tailored for the healthcare industry. It offers cloud-based platforms covering clinical skill training, talent management, patient safety education, and regulatory adherence tools, serving over 4,000 healthcare organizations including hospitals, clinics, and long-term care facilities nationwide.
ADMA vs HSTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $79.7M |
| Net Profit | $49.4M | — |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 3.0% |
| Net Margin | 35.5% | — |
| Revenue YoY | 18.4% | 7.4% |
| Net Profit YoY | -55.9% | — |
| EPS (diluted) | $0.20 | $0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $79.7M | ||
| Q3 25 | $134.2M | $76.5M | ||
| Q2 25 | $122.0M | $74.4M | ||
| Q1 25 | $114.8M | $73.5M | ||
| Q4 24 | $117.5M | $74.2M | ||
| Q3 24 | $119.8M | $73.1M | ||
| Q2 24 | $107.2M | $71.6M | ||
| Q1 24 | $81.9M | $72.8M |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $6.1M | ||
| Q2 25 | $34.2M | $5.4M | ||
| Q1 25 | $26.9M | $4.3M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $5.7M | ||
| Q2 24 | $32.1M | $4.2M | ||
| Q1 24 | $17.8M | $5.2M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 3.0% | ||
| Q3 25 | 38.0% | 9.9% | ||
| Q2 25 | 35.1% | 7.9% | ||
| Q1 25 | 30.4% | 6.0% | ||
| Q4 24 | 32.6% | 6.3% | ||
| Q3 24 | 33.1% | 8.9% | ||
| Q2 24 | 36.6% | 6.2% | ||
| Q1 24 | 26.7% | 7.8% |
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | 8.0% | ||
| Q2 25 | 28.1% | 7.2% | ||
| Q1 25 | 23.4% | 5.9% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | 7.8% | ||
| Q2 24 | 29.9% | 5.8% | ||
| Q1 24 | 21.7% | 7.2% |
| Q4 25 | $0.20 | $0.09 | ||
| Q3 25 | $0.15 | $0.20 | ||
| Q2 25 | $0.14 | $0.18 | ||
| Q1 25 | $0.11 | $0.14 | ||
| Q4 24 | $0.45 | $0.16 | ||
| Q3 24 | $0.15 | $0.19 | ||
| Q2 24 | $0.13 | $0.14 | ||
| Q1 24 | $0.08 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $36.2M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $354.0M |
| Total Assets | $624.2M | $520.4M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $36.2M | ||
| Q3 25 | $61.4M | $53.5M | ||
| Q2 25 | $90.3M | $52.1M | ||
| Q1 25 | $71.6M | $77.3M | ||
| Q4 24 | $103.1M | $59.5M | ||
| Q3 24 | $86.7M | $57.5M | ||
| Q2 24 | $88.2M | $46.1M | ||
| Q1 24 | $45.3M | $52.4M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $354.0M | ||
| Q3 25 | $431.2M | $349.2M | ||
| Q2 25 | $398.3M | $350.6M | ||
| Q1 25 | $373.4M | $362.8M | ||
| Q4 24 | $349.0M | $359.4M | ||
| Q3 24 | $231.9M | $355.5M | ||
| Q2 24 | $188.3M | $349.2M | ||
| Q1 24 | $153.7M | $344.9M |
| Q4 25 | $624.2M | $520.4M | ||
| Q3 25 | $568.7M | $499.9M | ||
| Q2 25 | $558.4M | $500.1M | ||
| Q1 25 | $510.6M | $524.0M | ||
| Q4 24 | $488.7M | $510.8M | ||
| Q3 24 | $390.6M | $502.8M | ||
| Q2 24 | $376.4M | $499.6M | ||
| Q1 24 | $350.9M | $511.6M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $13.2M |
| Free Cash FlowOCF − Capex | $34.6M | $13.0M |
| FCF MarginFCF / Revenue | 24.8% | 16.3% |
| Capex IntensityCapex / Revenue | 0.8% | 0.3% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $59.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $13.2M | ||
| Q3 25 | $13.3M | $18.0M | ||
| Q2 25 | $21.1M | $5.0M | ||
| Q1 25 | $-19.7M | $27.1M | ||
| Q4 24 | $50.2M | $11.2M | ||
| Q3 24 | $25.0M | $19.1M | ||
| Q2 24 | $45.6M | $6.5M | ||
| Q1 24 | $-2.2M | $20.9M |
| Q4 25 | $34.6M | $13.0M | ||
| Q3 25 | $-1.1M | $17.9M | ||
| Q2 25 | $18.7M | $2.7M | ||
| Q1 25 | $-24.4M | $26.0M | ||
| Q4 24 | $47.5M | $11.0M | ||
| Q3 24 | $24.0M | $18.8M | ||
| Q2 24 | $43.6M | $6.3M | ||
| Q1 24 | $-4.6M | $20.2M |
| Q4 25 | 24.8% | 16.3% | ||
| Q3 25 | -0.8% | 23.4% | ||
| Q2 25 | 15.3% | 3.6% | ||
| Q1 25 | -21.2% | 35.4% | ||
| Q4 24 | 40.4% | 14.8% | ||
| Q3 24 | 20.0% | 25.8% | ||
| Q2 24 | 40.7% | 8.8% | ||
| Q1 24 | -5.6% | 27.8% |
| Q4 25 | 0.8% | 0.3% | ||
| Q3 25 | 10.7% | 0.1% | ||
| Q2 25 | 2.0% | 3.1% | ||
| Q1 25 | 4.1% | 1.4% | ||
| Q4 24 | 2.3% | 0.3% | ||
| Q3 24 | 0.9% | 0.4% | ||
| Q2 24 | 1.9% | 0.2% | ||
| Q1 24 | 2.9% | 1.0% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 2.96× | ||
| Q2 25 | 0.62× | 0.93× | ||
| Q1 25 | -0.73× | 6.25× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 3.34× | ||
| Q2 24 | 1.42× | 1.55× | ||
| Q1 24 | -0.12× | 4.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
HSTM
| Subscription Services | $77.0M | 97% |
| Professional Services | $2.7M | 3% |
